Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

SYRS - Syros Pharmaceuticals Inc.


IEX Last Trade
1.64
-0.020   -1.220%

Share volume: 113,162
Last Updated: Fri 30 Aug 2024 09:59:53 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$1.66
-0.02
-1.21%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
31%
Profitability 25%
Dept financing 22%
Liquidity 66%
Performance 31%
Company vs Stock growth
vs
Performance
5 Days
-1.20%
1 Month
-73.80%
3 Months
-67.20%
6 Months
-77.19%
1 Year
-57.29%
2 Year
-79.53%
Key data
Stock price
$1.64
P/E Ratio 
-0.33
DAY RANGE
$1.61 - N/A
EPS 
-$3.88
52 WEEK RANGE
$1.48 - $8.17
52 WEEK CHANGE
-$0.58
MARKET CAP 
10.333 M
YIELD 
N/A
SHARES OUTSTANDING 
6.301 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/12/2024
BETA 
0.23
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$171,476
AVERAGE 30 VOLUME 
$522,966
Company detail
CEO: Nancy Simonian
Region: US
Website: https://syros.com/
Employees: 132
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

syros pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical r&d. central to the syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of syros' senior leadership. while this scientific approach has applications in many therapeutic areas, syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.

Recent news